Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes

Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide.